Long-term follow-up confirms survival benefits with adjuvant pembrolizumab in Stage III melanoma: KEYNOTE-054

Sponsored by MSD

Long-term data from KEYNOTE-054 presented at the recent ESMO 2020 Virtual Congress has confirmed the durability of the relapse-free survival (RFS) benefit of adjuvant pembrolizumab after complete resection of Stage III melanoma. The study also found that adjuvant pembrolizumab resulted in a significant reduction in the risk of distant metastases compared to placebo (HR:0.60; 95% ...

Already a member?

Login to keep reading.

© 2022 the limbic